Global DNA Sequencing Market- By Product (Instruments, Consumables, and Other Product Types), By End-User (Academics & Research Institutions, Pharmaceutical & Biotechnology Companies, Hospitals & Healthcare Organizations, and Other End Users), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032.
- Published date: Oct 2023
- Report ID: 101427
- Number of Pages: 388
- Format:
- keyboard_arrow_up
Quick Navigation
Report Overview
DNA Sequencing Market size is expected to be worth around USD 40.5 Billion by 2032 from USD 10.1 Billion in 2022, growing at a CAGR of 15.3% during the forecast period from 2023 to 2032.
The identification of DNA variations has been made possible by rapid advancements in bioinformatics and sequencing technology. Additionally, these advancements determine variants associated with elevated disease risk. A wide range of genes can now be tested on a single diagnostic platform due to the widespread use of Whole-genome Sequencing and Next-generation Sequencing, expanding the application of DNA sequencing in clinical diagnosis.
The identification of additional cancer targets or pathways and mutations for the development of pharmacological treatments is accelerated by personalized targeted sequencing of tumors. New fundamental information about oncology precision medicine is generated by the emergence of global projects utilizing NGS protocols.
Key Takeaway
- In 2022, the consumables category emerged as the top revenue generator.
- Next-generation sequencing was the leading contributor in terms of revenue when it comes to sequencing.
- The oncology field led the market, experiencing the highest Compound Annual Growth Rate (CAGR) during the forecast period of 2023 to 2032.
- Academic and research institutes held the largest market share among end-users.
- North America took the lead in 2022, with the highest revenue share at 44.3%.
- Looking ahead, Asia-Pacific is poised for rapid growth between 2023 and 2032.
Product Analysis
Consumables Segment Acquire the Largest Revenue Share
Consumables had the largest revenue share of the DNA sequencing market. A larger portion of the market is accounted for by the wide range of reagents and kits that can be used for every stage of library construction, including adapter ligation, DNA fragmentation, enrichment, quality control, and amplification. Most of these tools are compatible with low-input and formalin-fixed specimens, have ready-to-use components, and have workflows that are simplified and streamlined.
Sequencing Type Analysis
The Next-generation Sequencing Segment (NGS) accounted for the Largest Share of the
The Next-generation Sequencing Segment (NGS) is Expected to Hold a Significant Market Share and Follow the Same Trend Over the Forecast Period. The market for DNA sequencing was dominated by next-generation sequencing, which also contributed the most revenue. Genome sequencing has become cheaper, faster, and more accurate as a result of the falling cost of sequencing and these technologies’ radical advancements. In addition, the COVID-19 infection has increased the use of NGS technology as a routine clinical diagnostic test, boosting the segment’s revenue share.
In the DNA sequencing market, third-generation sequencing methods like Single-Molecule Real-Time and Nanopore sequencing are expected to grow at a significant CAGR over the forecast period. Because it eliminates the need for PCR amplification and speeds up sample preparation, this technology overcomes the shortcomings of second-generation methods. In addition, it generates lengthy reads that exceed a few thousand kilobases for the purpose of locating repetitive sites in complex genomes.
Application Analysis
Oncology Segment Dominated the Market for DNA Sequencing and Accounted for the Maximum Revenue Share
Oncology, from the DNA sequencing market, held the largest revenue share. The technology has enormous potential for treatment development and cancer diagnostics in clinical research. In recent times, NGS technology has demonstrated its capability as a low-cost, high-throughput method for rapidly identifying and characterizing clinically actionable genetic variants across multiple genes in a single test.
Clinicians and businesses alike are also well aware of the importance of these technologies in precision medicine and companion diagnostics. In this regard, the FDA approved the first liquid biopsy companion diagnostic that makes use of NGS technology to direct cancer treatment. The Guardant360 CDx assay encourages simultaneous mapping of multiple biomarkers of the tumor’s genomic alterations and less invasive testing.
End-User Analysis
The Academic & Research Institutes Segment Dominated the Market for DNA Sequencing with The Highest Revenue Share
Due to the widespread acceptance of NGS and Sanger technology in institutional and academic research projects, the market for DNA sequencing was dominated by the academic and research institutes segment with a revenue share. In addition, these organizations see an increase in revenue share as a result of an increase in funding and investment programs and an increase in demand for DNA sequencing products.
DNA Script and the Broad Institute, for instance, received USD 23.0 million from the Intelligence Advanced Research Projects Activity. For more than four years, the two organizations have been collaborating to investigate the possibility of integrating NGS and enzymatic DNA synthesis technology into a single instrument. Additionally, this consortium intends to collaborate with Illumina to make use of its sequencing-by-synthesis technology.
Key Market Segments
Based on Product
- Instruments
- Consumables
- Other Product Types
Based on Sequencing Type
- Next-generation Sequencing
- Sanger Sequencing
- Other Sequencing Types
Based on Application
- HLA Typing
- Oncology
- Clinical Investigation
Based on End-User
- Academics & Research Institutions
- Pharmaceutical & Biotechnology Companies
- Hospitals & Healthcare Organizations
- Other End Users
Drivers
Technological Advancements in DNA Sequencing and Increasing Application in Clinical Diagnosis & Drug Discovery
DNA sequencing technology advancements have significantly contributed to market expansion. The National Human Genome Research Institute (NHGRI) asserts that since the completion of the Human Genome Project, improvements and technological advancements have accelerated and decreased costs to the point where some laboratories are able to sequence trillions of bases annually.
Restraints
Data Privacy, High Costs, and Lack of Professional Expertise
Patients are very concerned about the privacy of their genetic data, which is stifling market expansion. Only 10% of biopharmaceutical companies completely anonymized their data, according to an NCBI study. Companies that do not anonymize data run the risk of data theft and exploitation by other businesses, which could impede market expansion. It has been discovered that the machines used in the various stages of DNA sequencing are pricey.
The National Human Genome Research Institute estimated that the procedure would cost approximately $300 million together. As a result, DNA sequencing’s market expansion may be hampered. DNA sequencing requires professional expertise, which is not always available. As a result, it takes longer to discover DNA sequencing niche methods and products, which impedes market expansion.
Opportunities
Acceptance of Newer Procedures
In the long run, market expansion may be aided by an increase in the use of more recent DNA sequencing methods. Additionally, newer approaches to cDNA sequencing are being discovered. This is also due to the fact that cDNA sequencing techniques are regarded as one of the most significant future market growth opportunities. A cDNA is a DNA strand produced in vitro from cell mRNA.
Regional Analysis
North America Dominates the Global DNA Sequencing Market During the Forecast Period
The market for genome sequencing is divided into North America, Europe, Asia-Pacific, the Middle East and Africa, and Latin America. It is expected that North America will hold the maximum genome sequencing market share of 44.3%. The rising need for personalized medicine, the growing demand for genome sequencing, and higher adoption rates of new technology are some of the factors that have contributed to the region’s dominance.
During the forecast period, Europe is anticipated to increase its market share. The market’s expansion in this region is likely to be fueled by the presence of research institutions and genomics-focused academics, awareness of significant genome sequencing applications in healthcare, and well-developed healthcare systems.
During the forecast period, Asia-Pacific is expected to grow at a relatively faster rate. Due to the large population in this region, it is anticipated that the growth will be fueled by government efforts to create a genomic database. In the future, precautionary and preventive medicine will make use of this database.
For instance, the Genomics for Public Health in India, also known as the IndiGen project, will be led by the Institute of Genomics and Integrative Biology (IGIB), which is a CSIR institute. In order to build a larger database, it intends to enroll thousands of Indians for whole genome sequencing within the next few years. The data will be crucial for developing baseline data, indigenous expertise, and capacity in the developing field of precision medicine. During the forecast period, the market in the Middle East & Africa, and Latin America may demonstrate greater acceptance and growth.
Key Regions
- North America
- The US
- Canada
- Mexico
- Western Europe
- Germany
- France
- The UK
- Spain
- Italy
- Portugal
- Ireland
- Austria
- Switzerland
- Benelux
- Nordic
- Rest of Western Europe
- Eastern Europe
- Russia
- Poland
- The Czech Republic
- Greece
- Rest of Eastern Europe
- APAC
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- Indonesia
- Malaysia
- Philippines
- Singapore
- Thailand
- Vietnam
- Rest of APAC
- Latin America
- Brazil
- Colombia
- Chile
- Argentina
- Costa Rica
- Rest of Latin America
- Middle East & Africa
- Algeria
- Egypt
- Israel
- Kuwait
- Nigeria
- Saudi Arabia
- South Africa
- Turkey
- United Arab Emirates
- Rest of MEA
Key Players Analysis
PerkinElmer, Inc. along with FDNA, introduced Face2Gene LABS to provide genomic services, in combination with Next-Generation Phenotyping (NGP) technologies.
There is intense competition in the global market for DNA sequencing with Illumina, Inc., Agilent Technologies; QIAGEN; Perkin Elmer, and Thermo Fisher Scientific; as the dominant players. In addition to making significant investments in distribution, production, and total quality management for portfolio expansion, these businesses are attempting to meet the rising demand from customers.
For instance, Face2Gene LABS was launched by PerkinElmer, Inc. and FDNA, an artificial intelligence company, to provide genomic services in conjunction with Next-Generation Phenotyping (NGP) technologies for quicker and more accurate diagnoses. By providing options for high-quality genomic testing that was also efficient, this initiative represented Perkin Elmer’s dedication to the diagnosis of patients with rare genetic disorders.
Listed below are some of the most prominent global DNA sequencing market players.Market Key Players
- Agilent Technologies Inc.
- PerkinElmer Inc.
- Bio-Rad Laboratories, Inc.
- Hoffmann-La Roche Ltd.
- Siemens AG
- Macrogen, Inc.
- Thermo Fisher Scientific, Inc.
- Roche Holdings AG
- Other Key Players
Recent Developments
- In October 2022- Two genome sequencing systems, the Revio long-read sequencing system, and the Onso short-read sequencing system will be available from PacBio. Revio also incorporates deep-learning techniques for detecting DNA methylation from standard sequencing libraries.
- In March 2022- Element Biosciences provided technical details about its Aviti DNA sequences. Element claims that the riff on sequencing-by-synthesis chemistry used in the new benchtop instrument reduces reagent consumption, resulting in savings of approximately USD 7 per Gb.
Report Scope
Report Features Description Market Value (2022) US$ 10.1 Bn Forecast Revenue (2032) US$ 40.5 Bn CAGR (2023-2032) 15.3% Base Year for Estimation 2022 Historic Period 2016-2022 Forecast Period 2023-2032 Report Coverage Revenue Forecast, Market Dynamics, COVID-19 Impact, Competitive Landscape, Recent Developments Segments Covered By Product- Instruments, Consumables, and Other Product Types; By Sequencing Type- Next-generation Sequencing, Sanger Sequencing, and Other Sequencing Types; By Application- HLA Typing, Oncology, and Clinical Investigation; and By End-User- Academics & Research Institutions, Pharmaceutical & Biotechnology Companies, Hospitals & Healthcare Organizations, and Other End Users. Regional Analysis North America – The US, Canada, & Mexico; Western Europe – Germany, France, The UK, Spain, Italy, Portugal, Ireland, Austria, Switzerland, Benelux, Nordic, & Rest of Western Europe; Eastern Europe – Russia, Poland, The Czech Republic, Greece, & Rest of Eastern Europe; APAC – China, Japan, South Korea, India, Australia & New Zealand, Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam, & Rest of APAC; Latin America – Brazil, Colombia, Chile, Argentina, Costa Rica, & Rest of Latin America; The Middle East & Africa – Algeria, Egypt, Israel, Kuwait, Nigeria, Saudi Arabia, South Africa, Turkey, United Arab Emirates, & Rest of MEA. Competitive Landscape Agilent Technologies Inc., PerkinElmer Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Siemens AG, Macrogen, Inc., Thermo Fisher Scientific, Inc., Roche Holdings AG, Other Key Players. Customization Scope Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements. Purchase Options We have three licenses to opt for: Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF) Frequently Asked Questions (FAQ)
What exactly is DNA sequencing?When determining nucleotide sequence (adenine-guanine-cytosine-thymine), DNA sequencing is used. This process can reveal valuable details about an individual's DNA, including the likelihood that they will develop certain diseases or respond to medication.
What is the market for DNA Sequencing?The DNA sequence market includes all companies that offer services, equipment and products related to DNA sequencing. This market has grown dramatically in recent times due to an increasing demand for genetic test and personalized medicine.
What are the various types of DNA-sequencing technologies that are available?Sanger sequencing is one of the most popular types of DNA-sequencing technologies. Next-generation sequencing and single-molecule sequencing are also available. NGS is the current most popular method because it allows for faster, more cost-effective and larger volumes of DNA to be sequenced.
What applications can DNA sequencing be used for?DNA sequencing is a powerful tool that can be applied to a variety of fields, such as agriculture, forensic science and environmental studies. It can help identify genetic mutations linked to diseases, track outbreaks of disease, study species genetic diversity, and much more.
- Agilent Technologies Inc. Company Profile
- PerkinElmer Inc.
- Bio-Rad Laboratories, Inc. Company Profile
- Hoffmann-La Roche Ltd.
- Siemens AG
- Macrogen, Inc.
- Thermo Fisher Scientific, Inc.
- Roche Holdings AG
- Other Key Players
- settingsSettings
Our Clients
Single User $4,599 $3,499 USD / per unit save 24% | Multi User $5,999 $4,299 USD / per unit save 28% | Corporate User $7,299 $4,999 USD / per unit save 32% | |
---|---|---|---|
e-Access | |||
Report Library Access | |||
Data Set (Excel) | |||
Company Profile Library Access | |||
Interactive Dashboard | |||
Free Custumization | No | up to 10 hrs work | up to 30 hrs work |
Accessibility | 1 User | 2-5 User | Unlimited |
Analyst Support | up to 20 hrs | up to 40 hrs | up to 50 hrs |
Benefit | Up to 20% off on next purchase | Up to 25% off on next purchase | Up to 30% off on next purchase |
Buy Now ($ 3,499) | Buy Now ($ 4,299) | Buy Now ($ 4,999) |